U.S. flag

An official website of the United States government

Format
Sort by

Send to:

Choose Destination

Search results

Items: 3

1.

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

(Submitter supplied) Glioblastoma is the most common primary malignant brain tumor in adults and associated with poor survival. Standard-of-care chemotherapy and radiation confer a median overall survival of under two years. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a randomized, multi institution clinical trial to evaluate immune responses and survival following neoadjuvant and/or adjuvant therapy with pembrolizumab, a programmed cell death protein 1 (PD-1) monoclonal antibody, in 35 patients with recurrent, surgically resectable glioblastoma. more...
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL21290
29 Samples
Download data: XLSX
2.

Illumina HiSeq 3000 (Homo sapiens)

Platform
Accession:
GPL21290
ID:
100021290
3.

Patient 27 tumor

Organism:
Homo sapiens
Source name:
Recurrent glioblastoma
Platform:
GPL21290
Series:
GSE121810
Download data
Sample
Accession:
GSM3447019
ID:
303447019
Format
Sort by

Send to:

Choose Destination

Supplemental Content

db=gds|term=GSM3447019[Accession]|query=1|qty=2|blobid=MCID_662a6bb6f4364867156631da|ismultiple=true|min_list=5|max_list=20|def_tree=20|def_list=|def_view=|url=/Taxonomy/backend/subset.cgi?|trace_url=/stat?
   Taxonomic Groups  [List]
Tree placeholder
    Top Organisms  [Tree]

Find related data

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center